#USA #Minneapolis #VentureMed Group #FLEX Vessel Prep™ #vascular diseases

VentureMed Group Expands Leadership and Clinical Evidence

VentureMed Group, Inc., an innovative player in the medical device sector specializing in arteriovenous (AV) access and peripheral arterial disease (PAD), has made significant strides by enhancing its commercial leadership team. This initiative aims to accelerate the growth of its flagship product, FLEX Vessel Prep™ System. Along with the leadership expansion, exciting new clinical evidence has emerged to support the system's efficacy in treating peripheral vascular diseases.

Driving Growth with Enhanced Leadership Team

The updated commercial leadership team at VentureMed is set to concentrate on three vital strategic areas:
1. Expanding Commercialization: The primary focus will be on furthering the commercial reach of the FLEX Vessel Prep™ System within the U.S. and select European markets.
2. Enhancing Reimbursement Strategies: The team will work on optimizing U.S. reimbursement frameworks to encourage adoption and ensure sustainable market presence.
3. Scaling Manufacturing: There will be a concerted effort to increase manufacturing capabilities to cater to rising demand amidst ongoing market expansion.

To spearhead these endeavors, VentureMed has welcomed several key industry veterans:

• - Dr. Jordan Knepper, MD, MSc: He steps in as Chief Medical Officer, succeeding Dr. John Pigott while remaining critical in advisory roles. Dr. Knepper is an esteemed vascular surgeon and Associate Professor at Michigan State University.
• - Pete Theirl: Assumes the role of Vice President of Global Sales, leveraging his extensive experience in medical device sales to facilitate global outreach.
• - Tom Michals: Taking on the Vice President of Marketing, his background from reputable firms like Boston Scientific and Medtronic will bolster strategic marketing initiatives.
• - Bruce Werner: Will serve as Senior Director of Sales Operations & Customer Fulfillment, ensuring that the focus on commercial execution and client satisfaction remains strong.

Other notable transitions include Dave Michaelson becoming VP of U.S. Sales and Kathy Leith taking on the role of VP of Market Access and Reimbursement.

Clinical Evidence Supporting FLEX Vessel Prep™ System

Supporting its growth efforts, VentureMed has also made strides in clinical research. A recently published peer-reviewed study titled The Benefit of Longitudinal Micro-incisions Prior to Paclitaxel-Coated Balloon Angioplasty (the BELONG Study), led by Dr. Daniel Periard, enhances the clinical evidence base of the FLEX Vessel Prep™ System. This prospective trial encompassed 41 patients and reported an impressive 97.5% freedom from clinically driven target lesion revascularization (CDTLR), showcasing sustained symptom relief at the 12-month mark. Such results indicate that utilizing the FLEX Vessel Prep™ with drug-coated balloons yields significant long-term advantages for patients with severe superficial femoral artery or popliteal lesions.

Positioned for a Breakout Year

According to Denis Harrington, President and CEO of VentureMed Group, the combination of an empowered leadership team and increasing clinical data positions the company favorably for accelerating the adoption of the FLEX Vessel Prep™ System and achieving its ambitious sales targets this fiscal year.

About VentureMed Group and the FLEX Vessel Prep™ System

VentureMed Group, Inc. leads the way in medical devices aimed at enhancing endovascular solutions for AV access and PAD interventions. The FLEX Vessel Prep™ System employs proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology to optimize vessel preparation, presenting itself as a notable improvement over conventional balloon approaches that rely on static pressure. By leveraging controlled motion, KEMIC creates precise micro-incisions, which contribute to significant benefits in patient outcomes, including reduced risks of restenosis.

The FLEX Vessel Prep™ System has obtained FDA 510(k) clearance and CE Mark approval, positioning it as a transformative tool in the treatment landscape for vascular diseases. For additional information about this groundbreaking technology, please visit VentureMed Group.